<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990392</url>
  </required_header>
  <id_info>
    <org_study_id>Kerrie-333333</org_study_id>
    <nct_id>NCT00990392</nct_id>
  </id_info>
  <brief_title>Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections</brief_title>
  <acronym>ToPICL</acronym>
  <official_title>Pilot Study: Topical Antibiotics for Prevention of ICU Central Line Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the overall central venous catheter related
      infection rate can be reduced by the application of Polysporin Triple Therapy ointment to the
      insertion site.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies in the dialysis population have found a reduction in local and system
      central venous catheter related infections with the application of topical antibiotics to the
      insertion point. One such study found a mortality benefit with Polysporin Triple Therapy
      ointment. We intend to determine if this preparation can reduce overall line infection rates
      in the ICU environment through its application at the time of line insertion and twice more
      the following week.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of practice to antibiotic impregnated catheters and large study published showing their
    efficacy. Made topical antibiotics obselete.
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall number of line related infections (local and blood borne)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of methicillin-resistant Staphylococcus Aureus (MRSA)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Blood Stream Infections</condition>
  <condition>Skin Diseases, Infectious</condition>
  <arm_group>
    <arm_group_label>Polysporin Triple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Petroleum jelly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polysporin Triple Therapy ointment</intervention_name>
    <description>Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.</description>
    <arm_group_label>Polysporin Triple Therapy</arm_group_label>
    <other_name>Polysporin Triple Therapy (gramicidin, polymixin, bacitracin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Petroleum Jelly</intervention_name>
    <description>Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vaseline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients admitted to the ICU requiring a central venous catheter

        Exclusion Criteria:

          -  previous line infection during same ICU stay

          -  CVC for hemodialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Reynolds, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fraser Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol. 2003 Jan;14(1):169-79.</citation>
    <PMID>12506149</PMID>
  </reference>
  <reference>
    <citation>James MT, Conley J, Tonelli M, Manns BJ, MacRae J, Hemmelgarn BR; Alberta Kidney Disease Network. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med. 2008 Apr 15;148(8):596-605.</citation>
    <PMID>18413621</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraser Health</investigator_affiliation>
    <investigator_full_name>Steve Reynolds</investigator_full_name>
    <investigator_title>Critical care Physician</investigator_title>
  </responsible_party>
  <keyword>Blood stream infections</keyword>
  <keyword>Catheter related infections</keyword>
  <keyword>Central venous catheter related infections</keyword>
  <keyword>Line sepsis</keyword>
  <keyword>Topical antibiotics</keyword>
  <keyword>Bacitracin</keyword>
  <keyword>Polymixin</keyword>
  <keyword>Gramicidin</keyword>
  <keyword>Polysporin Triple Therapy</keyword>
  <keyword>Intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Gramicidin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

